Injection Site Reactions Because tirzepatide is administered subcutaneously (under the skin), injection site reactions are relatively common: Redness, itching, or swelling at the injection site Minor bruising or tenderness Warmth or mild discomfort These reactions are usually mild and self-limiting
Because the resulting synthetic molecule can be fully characterized through structural analysis (unlike complex biologics), regulators can treat it as a conventional generic drug rather than a biosimilar
The most common side effects are gastrointestinal, including nausea, diarrhoea, and decreased appetite
Safety monitoring parameters: Gastrointestinal tolerance: Keep a symptom diary during the first 8 weeks, noting severity and duration of nausea, vomiting, or diarrhea Hydration status: Monitor for signs of dehydration, especially if experiencing gastrointestinal side effects Abdominal symptoms: Report persistent or severe abdominal pain promptly for evaluation of potential pancreatitis or gallbladder disease Renal function: Assess at baseline and periodically per ADA guidelines (at least annually
p 0.01), concurrently inhibiting gonadotropin-releasing hormone receptor (GnRHR) gene expression in the anterior pituitary (by 80%, p 0.01) and reducing plasma LH concentrations (by 25%, p 0.05)
doi: 10.3390/molecules24010009 84 WangWLiuWFidlerTWangYTangYWoodsBet al